Boston Scientific (BSX) FY2024 results: revenue $16.7 billion, up 17.6% on the year
Boston Scientific Corp. (BSX) reported revenue of $16.7 billion for fiscal 2024, the year ended 31 December 2024, up 17.6% on the year before. Net income was $1.9 billion, up 18.0%, and diluted earnings per share $1.25. The figures are the company's own, from the 10-K it filed with the SEC on 18 February 2025.
Revenue
$16.7 billion
+17.6% on the year
FY2017FY2024
Operating margin
15.5%
16.5% a year earlier
FY2017FY2024
Net income
$1.9 billion
+18.0% on the year
FY2017FY2024
Diluted EPS
$1.25
+16.8% on the year
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
3,435
2,503
1,526
+37.2%
Capital expenditure
790
711
588
+11.1%
Free cash flow
2,645
1,792
938
+47.6%
Free cash flow margin
15.8%
12.6%
7.4%
Cash from investing
-5,687
-2,574
-2,011
Cash from financing
1,814
5.0
-548
+36,180.0%
Depreciation and amortisation
1,269
1,196
1,136
+6.1%
Share-based compensation
266
233
220
+14.2%
Buybacks
n/a
n/a
0.0
Dividends paid
0.0
28.0
55.0
Diluted shares, weighted
1,486m
1,464m
1,440m
+1.5%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
21,770
19,282
17,573
+12.9%
Non-controlling interest
233
248
0.0
-6.0%
Debt
10,746
9,102
8,915
+18.1%
Operating lease liabilities
401
390
347
+2.8%
Other liabilities
6,245
6,114
5,634
+2.1%
Total liabilities and equity
39,395
35,136
32,469
+12.1%
Fixed assets
3,294
2,859
2,446
+15.2%
Goodwill
17,089
14,387
12,920
+18.8%
Intangible assets
6,684
6,003
5,902
+11.3%
Securities held for sale or to maturity
n/a
n/a
1.0
Cash and equivalents
414
865
928
-52.1%
Inventory
2,810
2,484
1,867
+13.1%
Other assets
9,104
8,538
8,405
+6.6%
Total assets
39,395
35,136
32,469
+12.1%
10-K for the year ended 31 December 2024, filed 18 February 2025: the filing.